• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clene Inc. - Common Stock (NQ:CLNN)

    9.420 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 9.420
    Bid (Size) 9.330 (1)
    Ask (Size) 12.88 (1)
    Prev. Close 9.420
    Today's Range 9.420 - 9.420
    52wk Range 2.280 - 11.06
    Shares Outstanding 128,404,735
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Landmark Study Shows How Menopause Influences the Symptoms of Multiple Sclerosis
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results at ECTRIMS 2025
    Via Investor Brand Network

    Performance

    YTD
    +74.8%
    +74.8%
    1 Month
    +42.1%
    +42.1%
    3 Month
    +146.0%
    +146.0%
    6 Month
    +214.0%
    +214.0%
    1 Year
    +83.6%
    +83.6%

    More News

    Read More
    New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease
    Via Investor Brand Network
    Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease
    Via Investor Brand Network
    MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model
    Via Investor Brand Network
    Research Uncovers Possible Way to Repair Myelin in MS Patients
    Via Investor Brand Network
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference
    Via Investor Brand Network
    InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Late-Stage Momentum in Neuro Pipeline
    Via Investor Brand Network
    Pioneering Therapy Could Slow the Effects of Aging
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026
    Via Investor Brand Network
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy
    Via Investor Brand Network
    Clene Posts 70% Revenue Drop in Q2
    Via The Motley Fool
    InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20
    Via Investor Brand Network
    Parkinson’s-Gut Bacteria Link Suggests Surprisingly Simple Treatment Option
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference
    Via Investor Brand Network
    New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Builds Momentum to Bring New Hope to Neuro Patients
    Via Investor Brand Network
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Individuals Who Develop Multiple Sclerosis Have More Doctor Visits Decades Before Their Diagnosis
    Via Investor Brand Network
    Preclinical Study Finds a Way to Reverse Symptoms of Parkinson’s in Mice
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025
    Via Investor Brand Network
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
    Via Investor Brand Network

    Frequently Asked Questions

    Is Clene Inc. - Common Stock publicly traded?
    Yes, Clene Inc. - Common Stock is publicly traded.
    What exchange does Clene Inc. - Common Stock trade on?
    Clene Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Clene Inc. - Common Stock?
    The ticker symbol for Clene Inc. - Common Stock is CLNN on the Nasdaq Stock Market
    What is the current price of Clene Inc. - Common Stock?
    The current price of Clene Inc. - Common Stock is 9.420
    When was Clene Inc. - Common Stock last traded?
    The last trade of Clene Inc. - Common Stock was at 10/08/25 04:00 PM ET
    What is the market capitalization of Clene Inc. - Common Stock?
    The market capitalization of Clene Inc. - Common Stock is 1.21B
    How many shares of Clene Inc. - Common Stock are outstanding?
    Clene Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.